The study of fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant central nervous system tumor.

The study of fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant central nervous system tumor. - Five-aminolevulinic acid for fluorescence-guided resection of malignant brain tumor.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007872

Enrollment

Registered

2012-05-15

Start date

2012-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumor of central nervous system

Interventions

Oral administration of 5-ALA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet all of the requirements described bellow are included. 1. Patients who are hospitalized at Kobe university hospital in order to undergo surgery. 2. Patients who are diagnosed with malignant tumor of CNS preoperatively. 3. Patients who provide a wittern informed consent.

Exclusion criteria

Exclusion criteria: Patients who meet any of the conditions described bellow are excluded. 1) Patients with porphyria 2) Patients with hypersensitivity to 5-ALA or porphyrins 3) In case of renal insufficiency (serum creatinine is more than 2.0 mg/dL) 4) In case of hepatic insufficiency (total bilirubin >3 mg/dL, gamma-GTP >100 U/L, ptptprombin time <60%) 5) In case of known or suspected pregnancy,or woman who are breast-feeding.

Design outcomes

Primary

Measure	Time frame
resection rate	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026